Most importantly, the action of SGLT2 inhibitors to promote ketogenesis is primarily a feature of the action of these drugs in patients with type 2 diabetes; this ketogenic effect is attenuated in nondiabetic patients [18]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.